

## Zepbound (tirzepatide)

- Indications: To treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
- Age:  $\geq 18$  years
- Criteria:
  - Prescribed by or in consultation with a sleep specialist, pulmonologist, or other provider experienced in treating OSA.
  - Moderate to severe OSA as diagnosed by polysomnography with an apnea-hypopnea index (AHI)  $\geq 15$  events per hour.
  - BMI  $\geq 30$  kg/m<sup>2</sup>
  - Provide current height and weight measurements (within the last 90 days)
  - Patient meets FDA-approved prescribing information clinical parameters for use (i.e. no contraindications, appropriate screening and monitoring have been completed)
  - If the patient has a diagnosis of Type 2 Diabetes Mellitus (T2DM), they must use a GLP-1 receptor agonist indicated for T2DM.
  - Will not be used concurrently with other tirzepatide-containing products or GLP-1 receptor agonists.
- Quantity Limitations: Four (4) pens/28 days, any strength
- Initial Approval Duration: Six (6) months
- Renewal Criteria:
  - Prescriber attestation of continued clinical benefit and subsequent evaluation and monitoring performed.
  - Renewal requests will NOT be authorized if the member's BMI is  $< 30$  kg/m<sup>2</sup>
  - Therapy beyond 12 months will require repeat documentation confirming moderate to severe OSA and annually thereafter.
  - Renewal Approval Duration: Six (6) months